Healthcore, Inc.
Principal Scientist
Csl Behring Feb 2017 - May 2018
Director, Medical Affairs, Cardiovascular
Novartis May 2015 - Sep 2016
Global Market Access Director, Near Patient Testing
Novartis Oncology Sep 2013 - May 2015
Worldwide Health Outcomes, Value, and Access - Oncology New Products - Companion Diagnostics
Ejs Health Solutions Jan 2013 - Dec 2014
President
Education:
Illinois College 1986 - 1990
Doctorates, Doctor of Pharmacy, Pharmacy
University of Illinois at Urbana - Champaign 1981 - 1985
Bachelors, Bachelor of Science, Biology
Skills:
Pharmaceutical Industry Clinical Trials Oncology Clinical Research Clinical Development Medical Affairs Outcomes Research Health Economics Healthcare Biotechnology Clinical Pharmacology Diabetes Hospitals Personalized Medicine Drug Development Research Pharmacogenomics Pharmacy Benefit Management Strategic Planning Data Analysis R&D Pharmacoeconomics Management Data Mining Epidemiology Pharmacists Pharmacogenetics Publications Clinical Pharmaceuticals Statistics Diagnostics Budgeting Policy Education Health Outcomes Corporate Communications Executives Cardiovascular Medicine Press Releases Scientific Intelligence Adherence Pharmacy Benefits Management Strategic Leadership Public Speaking Thought Leadership Patient Advocacy Quality Assurance Translational Research Consulting
"There are other therapeutic alternatives that could be prescribed that would not have the same potential for interaction," said study co-author Eric Stanek, who called for increased surveillance of patient prescribing.
Date: Mar 16, 2012
Category: Health
Source: Google
Cancer Drug Benefits May Be Harmed by Effect of Other Medicines
Anything that may reduce a cancer drugs effectiveness isobviously very concerning, Eric Stanek, vice president ofresearch at Medco and a study author, said in an interview.You dont want to wait and see if the cancer comes back torealize there is a problem.